

Message Text

UNCLASSIFIED

PAGE 01 TOKYO 06861 230843Z

46

ACTION OES-05

INFO OCT-01 EA-10 ISO-00 HEW-06 (ISO) W
----- 036201

R 230818Z MAY 75

FM AMEMBASSY TOKYO

TO SECSTATE WASHDC 350

UNCLAS TOKYO 6861

OES/SCI/BMP FOR DR. M.S. BEAUBIEN

DEPT PASS TO NATIONUL CANCER INSTITUTE FOR DR. WILLIAM TERRY

E.O. 11652: N/A

TAGS: TBIO, JA

SUBJECT: MARUYAMA CANCER VACCINE

REF: (A) STATE 103521, (B) TOKYO 5374, (C) STATE 69856

1. EMBOFF DELIVERED LETTER CONTAINING SUBSTANCE OF REFTEL (A) TO DRS. MARUYAMA AND FUJITA (MARUYAMA'S CO-AUTHOR) ON MAY 22. MARUYAMA EXPRESSED APPRECIATION THAT HIS VACCINE CAN NOW ENTER US FOR INVESTIGATIONAL PURPOSES. EMBOFF EMPHASIZED LIMITED NATURE OF FDA APPROVAL AND FACT THAT EMBASSY CANNOT ACT AS INTERMEDIARY. EMBOFF REQUESTED THAT FORM LETTER CITED PARA 4, REFTEL (A), NOT BE SENT TO US CITIZENS.

2. DR. FUJITA COMMENTED THAT IMMUNOTHERAPEUTIC APPROACH FOR TREATMENT OF CANCER HAS WON INCREASING ACCEPTANCE, EVEN AMONG JAPANESE MEDICAL PROFESSION, SINCE ELEVENTH INTERNATIONAL CANCER CONGRESS IN ITALY IN OCTOBER 1974, WHICH MARUYAMA AND FUJITA ATTENDED. HOWEVER, WHEN EMBOFF ASKED ABOUT PROSPECTS FOR APPROVAL BY GOJ MINISTRY OF HEALTH AND WELFARE (MHW) AND FOR COMMERCIAL PRODUCTION OF VACCINE, DR. FUJITA GAVE NO SPECIFICS, CITING ONLY LENGTHY MHW CLEARANCE PROCESS AND NEED FOR "COOPERATION" FROM JAPANESE PHARMACEUTICAL COMPANIES TO ACHIEVE COMMERCIAL PRODUCTION. FUJITA, WHO ACTED AS MARUYAMA'S SPOKSMAN THROUGHOUT INTERVIEW,
UNCLASSIFIED

UNCLASSIFIED

PAGE 02 TOKYO 06861 230843Z

EMPHASIZED THAT MARUYAMA HAS BEEN RELATIVELY

UNINTERESTED IN WORKING TO MAKE HIS VACCINE COMMERCIAL-
LY AVAILABLE. FUJITA DID NOT CHALLENGE EMBOFF'S
SURMISE THAT TO MAKE VACCINE COMMERCIAL-
LY AVAILABLE MIGHT TAKE THREE OR FOUR YEARS.

3. EMBASSY'S LETTER REQUESTS MARUYAMA TO REPLY DIRECTLY
TO FDA IND STAFF WITH REQUESTED DETAILS ON MANUFACTURE OF
VACCINE.

4. EMBASSY WILL ADVISE IF MHW APPROVES MARUYAMAJS
VACCINE.
HODGSON

UNCLASSIFIED

NNN

Message Attributes

Automatic Decaptioning: X
Capture Date: 01 JAN 1994
Channel Indicators: n/a
Current Classification: UNCLASSIFIED
Concepts: RESEARCH, CANCER, VACCINES
Control Number: n/a
Copy: SINGLE
Draft Date: 23 MAY 1975
Decaption Date: 01 JAN 1960
Decaption Note:
Disposition Action: n/a
Disposition Approved on Date:
Disposition Authority: n/a
Disposition Case Number: n/a
Disposition Comment:
Disposition Date: 01 JAN 1960
Disposition Event:
Disposition History: n/a
Disposition Reason:
Disposition Remarks:
Document Number: 1975TOKYO06861
Document Source: CORE
Document Unique ID: 00
Drafter: n/a
Enclosure: n/a
Executive Order: N/A
Errors: N/A
Film Number: D750181-0947
From: TOKYO
Handling Restrictions: n/a
Image Path:
ISecure: 1
Legacy Key: link1975/newtext/t19750521/aaaaastu.tel
Line Count: 73
Locator: TEXT ON-LINE, ON MICROFILM
Office: ACTION OES
Original Classification: UNCLASSIFIED
Original Handling Restrictions: n/a
Original Previous Classification: n/a
Original Previous Handling Restrictions: n/a
Page Count: 2
Previous Channel Indicators: n/a
Previous Classification: n/a
Previous Handling Restrictions: n/a
Reference: 75 STATE 103521, 75 TOKYO 5374, 75 STATE 69856
Review Action: RELEASED, APPROVED
Review Authority: CunninFX
Review Comment: n/a
Review Content Flags:
Review Date: 29 JUL 2003
Review Event:
Review Exemptions: n/a
Review History: RELEASED <29 JUL 2003 by maginmm>; APPROVED <27 JAN 2004 by CunninFX>
Review Markings:

Margaret P. Grafeld
Declassified/Released
US Department of State
EO Systematic Review
05 JUL 2006

Review Media Identifier:
Review Referrals: n/a
Review Release Date: n/a
Review Release Event: n/a
Review Transfer Date:
Review Withdrawn Fields: n/a
Secure: OPEN
Status: NATIVE
Subject: MARUYAMA CANCER VACCINE
TAGS: TBIO, JA, (MARUYAMA, CHISATO)
To: STATE
Type: TE
Markings: Margaret P. Grafeld Declassified/Released US Department of State EO Systematic Review 05 JUL 2006